JP2021504479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504479A5 JP2021504479A5 JP2020546307A JP2020546307A JP2021504479A5 JP 2021504479 A5 JP2021504479 A5 JP 2021504479A5 JP 2020546307 A JP2020546307 A JP 2020546307A JP 2020546307 A JP2020546307 A JP 2020546307A JP 2021504479 A5 JP2021504479 A5 JP 2021504479A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pirfenidone
- composition according
- dose
- ubenimex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762591667P | 2017-11-28 | 2017-11-28 | |
| US62/591,667 | 2017-11-28 | ||
| PCT/US2018/062645 WO2019108551A1 (en) | 2017-11-28 | 2018-11-27 | Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021504479A JP2021504479A (ja) | 2021-02-15 |
| JP2021504479A5 true JP2021504479A5 (enExample) | 2022-01-06 |
Family
ID=66664242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546307A Pending JP2021504479A (ja) | 2017-11-28 | 2018-11-27 | 非アルコール性脂肪性肝炎の処置のための方法および医薬組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210369693A1 (enExample) |
| EP (1) | EP3716975A4 (enExample) |
| JP (1) | JP2021504479A (enExample) |
| CN (1) | CN111386115A (enExample) |
| AU (1) | AU2018375298A1 (enExample) |
| CA (1) | CA3082178A1 (enExample) |
| WO (1) | WO2019108551A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102399254B1 (ko) | 2016-09-28 | 2022-05-17 | 아이거 바이오파마슈티컬스 인코포레이티드 | 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물 |
| WO2023220003A1 (en) * | 2022-05-10 | 2023-11-16 | Opko Pharmaceuticals, Llc | Topical ophthalmic pirfenidone-loaded liposomes to increase the therapeutic activity of the drug in cornea and useful for prevention or therapy of corneal haze |
| CN118680879A (zh) * | 2024-06-03 | 2024-09-24 | 贵州医科大学 | 一种用于负载吡非尼酮的口服肝靶向纳米乳剂及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1098249C (zh) * | 1995-06-21 | 2003-01-08 | 国家医药管理局四川抗菌素工业研究所 | 乌比美克及含乌比美克的药物组合物治疗病毒性肝炎的用途 |
| AU2001230605A1 (en) * | 2000-02-09 | 2001-08-20 | Shionogi And Co., Ltd. | Apoptosis inhibitor |
| US20080025986A1 (en) * | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
| EP2827849A4 (en) * | 2012-03-23 | 2015-11-18 | Univ Leland Stanford Junior | TREATMENT OF PULMONARY HYPERTONIA WITH LEUKOTRIENHEMMERN |
| CA2819967C (en) * | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
| MX2018005540A (es) * | 2015-11-06 | 2018-11-09 | Gemphire Therapeutics Inc | Tratamiento de dislipemia mixta. |
| WO2017108744A1 (de) * | 2015-12-22 | 2017-06-29 | Bayer Pharma Aktiengesellschaft | Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| KR102399254B1 (ko) * | 2016-09-28 | 2022-05-17 | 아이거 바이오파마슈티컬스 인코포레이티드 | 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물 |
| MX364040B (es) * | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
-
2018
- 2018-11-27 US US16/768,000 patent/US20210369693A1/en not_active Abandoned
- 2018-11-27 EP EP18883621.7A patent/EP3716975A4/en not_active Withdrawn
- 2018-11-27 JP JP2020546307A patent/JP2021504479A/ja active Pending
- 2018-11-27 CN CN201880076561.6A patent/CN111386115A/zh active Pending
- 2018-11-27 AU AU2018375298A patent/AU2018375298A1/en not_active Abandoned
- 2018-11-27 CA CA3082178A patent/CA3082178A1/en active Pending
- 2018-11-27 WO PCT/US2018/062645 patent/WO2019108551A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2917489C (en) | Drug for treatment of nonalcoholic fatty liver disease | |
| ES2646816T3 (es) | Composiciones de dosificaciones orales de liberación retardada que contienen CDDO-Me amorfo | |
| JP2022180461A5 (enExample) | ||
| IL314360A (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
| RU2018133298A (ru) | Способы применения агонистов fxr | |
| UA110853C2 (uk) | Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування | |
| JP2018507914A5 (enExample) | ||
| JP2007506775A5 (enExample) | ||
| JP2018513171A5 (enExample) | ||
| JP2021504479A5 (enExample) | ||
| WO2010103544A3 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| NZ711179A (en) | Oral formulations of deferasirox | |
| JP2021509395A5 (enExample) | ||
| JP2015516418A5 (enExample) | ||
| FI3706724T3 (fi) | Suun kautta otettavia rifamysiini sv -koostumuksia | |
| JP2019529566A5 (enExample) | ||
| JP2019218379A5 (enExample) | ||
| JP2022082819A (ja) | 医薬組成物 | |
| JP2020522560A5 (enExample) | ||
| JP2011507853A5 (enExample) | ||
| TWI676476B (zh) | 用於減少體重及減少體脂肪的組合物及其醫藥品與應用 | |
| CN101094647A (zh) | 非诺贝特与脂肪酸酯的稳定组合物 | |
| RU2020121222A (ru) | Агонисты fxr для лечения заболеваний печени | |
| JP2021504370A5 (enExample) | ||
| JP2017515858A5 (enExample) |